Amgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions

THOUSAND OAKS, Calif., Dec. 11, 2018 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced a novel multi-year collaboration with Magellan Rx Management, the pharmacy benefit management division of Magellan Health, that will leverage each company’s capabilities and resources to identify clinical gaps for some of the healthcare system’s most difficult-to-treat diseases. Based on Amgen and Magellan’s extensive expertise in complex areas of health and specialty populations, the initial projects will focus on improving patient outcomes for the treatment of osteoporosis and migraine. These projects mark Amgen’s first value-based collaboration with a pharmacy benefit manager (PBM).

“Amgen’s collaboration with Magellan Rx demonstrates our commitment to cultivating deeper, more meaningful relationships with PBMs, moving beyond the typical transactional agreements towards a model that truly improves care for patients while at the same time lowering costs,” said Peter Juhn, M.D., vice president of Global Value-Based Partnerships at Amgen. “This relationship creates a nexus of capabilities between Amgen and Magellan Rx. Together, we can drive innovative solutions to manage the fastest-growing high-cost areas of healthcare.”

Amgen and Magellan Rx’s osteoporosis project will aim to improve disease management in patients following a bone fracture. The likelihood of a second fracture in these osteoporosis patients increases three to five times, but only a quarter are evaluated and treated. Importantly, the project will also help determine if an individualized program to identify high-risk osteoporosis patients and intervene with resources and information will lead to better health outcomes, and consequently reduce costs for the healthcare system.

The Magellan Rx team will contribute resources, including teaching patients how to care for fractures, the risks of not taking medication as prescribed, and of changes they can make to their lifestyle to minimize future fractures. Resources will also include education for healthcare providers to help them identify the obstacles that prevent patients from optimally managing their condition and treatment plan, as well as tools to help providers educate their patients on the critical aspects of their condition and care.

Amgen and Magellan Rx also share an interest in understanding the unmet needs of people living with migraines and finding opportunities to improve the treatment experience, especially non-opioid alternatives. Currently, the financial and clinical burdens of this disease are not well understood by payers and employers, despite the fact that U.S. employers lose an estimated $11 billion because of migraine each year, largely due to missed work days and lost productivity.1

Magellan Method, Magellan Rx’s innovation division, will work with its employer and payer customers to gain real-world patient insights around migraine management, including the cost of migraine, gaps in treatment and opportunities to improve care. These insights will help inform the development of educational materials for employers, payers and patients around the burden of migraines to support improvements in patient outcomes and the utilization of treatment resources.

“We’re collaborating to evaluate the impact of interventions in patients with migraine or osteoporosis,” said Steve Michurski, senior vice president of Trade Relations at Magellan Rx. “We have a unique testing opportunity that can offer real-world evidence. This relationship combines our collective capabilities and resources to create value and insights for patients and providers across healthcare systems.”

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit and follow us on

Amgen and Value-Based Programs

As a collaborative partner within the healthcare system, Amgen believes that engaging in value-based programs with stakeholders creates mutually beneficial opportunities to improve costs, quality of care and the patient experience.

Globally, Amgen is engaged in over 100 distinct, value-based projects, spanning disease state collaborations, risk sharing and outcomes-based agreements. The Company has more than 25 ongoing partnerships in the United States with PBMs, integrated delivery health networks, Medicaid plans and technology companies, and has several other collaborations under development.

About Magellan Rx Management

Magellan Rx Management is a full-service, next generation PBM with a value-driven approach that moves past the traditional volume-focused thinking to deliver meaningful solutions. Our services expand beyond traditional core services to help our customers and members solve complex pharmacy challenges by connecting them to the people, technology and information they need to make smarter healthcare decisions. As pioneers in managing specialty spend both on the prescription and medical benefit, we are effectively-positioned to continue delivering thought-leading solutions in this complex and rapidly growing area of healthcare to help people live healthier lives. Magellan Rx Management is a division of Magellan Health, Inc. For more information, visit

1 Hawkins K, et al. Indirect cost burden of migraine in the United States. J Occup Environ Med. 2007 Apr; 49(4):368-74.

Check Also

Aimmune Agrees to be Acquired by Nestlé Health Science for $2 Billion

BRISBANE, Calif.–(BUSINESS WIRE)–Aug. 31, 2020– Aimmune Therapeutics Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments …